Antiretroviral Therapy and Adverse Pregnancy Outcomes in People Living with HIV | NEJM
Skip to main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn …

Low‐and middle‐income countries (LMIC) face unique challenges with regard to the
establishment of robust pharmacovigilance systems capable of generating data to inform …

Abstract Background The World Health Organization recommends dolutegravir with two
nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human …

Background Weight gain effects of individual antiretroviral drugs are not fully understood.
We investigated associations between a prespecified clinically significant increase (> 7%) in …

Background Due to the high prevalence of resistance to NNRTI-based ART since 2018,
consolidated recommendations from the WHO have indicated dolutegravir as the preferred …

Numerous studies have detected a greater likelihood of excess weight gain with specific
antiretrovirals (ARVs), particularly tenofovir alafenamide and integrase inhibitors, as …

There is a growing body of evidence from both observational and randomised trials
implicating integrase inhibitors, particularly dolutegravir and bictegravir, with the …

Efavirenz (Sustiva®) is a first-generation non-nucleoside reverse transcriptase inhibitor
(NNRTI) used to treat human immunodeficiency virus (HIV) type 1 infection or to prevent the …

Background WHO guidelines recommend dolutegravir plus two nucleoside reverse
transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first …

Background Children with human immunodeficiency virus type 1 (HIV-1) infection have
limited options for effective antiretroviral treatment (ART). Methods We conducted an open …